MSD’s CAPVAXIVE vaccine has demonstrated promising results from the STRIDE-8 Phase III trial, which showed positive immune ...

The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults. The 21-valent ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from STRIDE-8, a Phase 3 trial evaluating CAPVAXIVE™ (Pneumococcal ...

Merck (NYSE:MRK) announced Wednesday that its 21-valent pneumococcal vaccine, Capvaxive, approved in the U.S. to prevent pneumonia, generated positive immune responses in a Phase 3 trial for ...

Merck’s STRIDE-8 phase 3 trial of Capvaxive demonstrates positive immune responses in adults with increased risk for pneumococcal disease: Rahway, New Jersey Thursday, October 1 ...

We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates ...

Respiratory virus season has arrived, and hopefully you’re up to date on vaccinations that can help prevent infectious ...

RAHWAY, N.J. - Merck & Co., Inc. (NYSE: MRK) has announced positive results from the STRIDE-8 Phase 3 trial of its pneumococcal 21-valent conjugate vaccine, CAPVAXIVE, presented at IDWeek 2024.

Merck's (MRK) monoclonal antibody clesrovimab shows cuts RSV infections by 60% in infants, with a strong safety profile. Read ...

RAHWAY, N.J. - Merck & Co., Inc. (NYSE: MRK) has announced positive results from the STRIDE-8 Phase 3 trial of its pneumococcal 21-valent conjugate vaccine, CAPVAXIVE, presented at IDWeek 2024. The ...